Supplementary Material for: Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review

Langerhans cell histiocytosis (LCH) is a rare neoplastic disease characterized by infiltration of histiocytes and dendritic cells into body organs. While treatment is better established in pediatrics, there is still no consensus on therapy in the adult population. Imatinib has shown promising results in some case reports and a small clinical trial. We present here a fifty-nine-year-old patient with LCH in the lung, liver, and bone who responded well to an imatinib dose of 100 mg daily. Her symptoms improved within 3 months of treatment, and subsequent positron emission tomography-computed tomography (PET/CT) showed resolution of 18F-fluorodeoxyglucose (FDG)-avid lesions.

朗格汉斯细胞组织细胞增生症（Langerhans cell histiocytosis, LCH）是一种罕见的肿瘤性疾病，以组织细胞与树突状细胞浸润机体各脏器为典型病理特征。目前儿科领域的治疗方案已相对成熟规范，但成人患者群体的治疗仍未达成统一共识。伊马替尼在部分病例报告及小型临床试验中已展现出令人鼓舞的疗效。本文报告1例累及肺、肝与骨骼的LCH女性患者，该患者接受每日100mg伊马替尼治疗后获得良好应答：其临床症状于治疗3个月内得到显著改善，后续正电子发射计算机断层显像-计算机断层扫描（PET/CT）检查显示，18F-氟代脱氧葡萄糖（18F-fluorodeoxyglucose, FDG）高摄取病灶完全消退。